Research programme: RNA vaccines - Gylden Pharma
Latest Information Update: 22 Oct 2024
At a glance
- Originator Emergex Vaccines
- Developer George Mason University; Gylden Pharma
- Class RNA vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 17 Oct 2024 Emergex Vaccines is now called Gylden Pharma
- 28 May 2024 No recent reports of development identified for research development in Viral-infections(Prevention) in United Kingdom (Parenteral)
- 22 Apr 2020 Emergex Vaccines and George Mason University agree to co-develop RNA vaccines for Viral infections